Cellular Discovery Platform for Neurodegenerative Disease Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases associated with protein aggregation, such as Parkinson's and Alzheimer's, are inadequate in modifying the disease course effectively.
Innovation Solution
A method utilizing yeast models that express neurodegeneration-associated proteins like alpha-synuclein, TDP-43, or A-beta, combined with human induced pluripotent stem cell-derived neurons, to identify candidate therapeutic agents that reduce toxicity and modulate disease-related phenotypes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for neurodegenerative diseases, then treatment is provided, but the disease course is not effectively modified
Solution Approach 1:
The patent applies preliminary action by using yeast models to screen and identify candidate therapeutic agents before they are tested in human neurons. This preliminary screening in a simplified model system allows for the pre-selection of compounds that show promise in reducing toxicity and modulating disease phenotypes, thereby improving the reliability of disease-modifying therapies before committing to more complex and resource-intensive human trials
Solution Approach 2:
The patent uses human induced pluripotent stem cell-derived neurons as an intermediary system between simple yeast models and actual human patients. These patient-specific neurons serve as a bridge, allowing therapeutic candidates identified in yeast to be validated in a more physiologically relevant human neural system, thereby enhancing the overall therapeutic effectiveness while maintaining a systematic approach to drug development
2Productivity
If yeast models expressing neurodegeneration-associated proteins are used, then candidate therapeutic agents can be identified, but the complexity of the system increases
Solution Approach 1:
The patent applies segmentation by dividing the drug discovery process into distinct stages: first screening in simplified yeast models expressing specific neurodegeneration-associated proteins (alpha-synuclein, TDP-43, A-beta), then validating hits in human neurons. This segmentation allows each stage to focus on specific aspects of disease pathology, improving drug discovery efficiency while managing complexity through systematic progression from simple to complex models
Solution Approach 2:
The yeast model system is designed with multi-functionality, serving as a universal platform that can express multiple different neurodegeneration-associated proteins (alpha-synuclein, TDP-43, A-beta) and screen for various therapeutic mechanisms simultaneously. This universal yeast platform reduces the need for separate model systems for different proteins, thereby improving productivity while controlling overall system complexity
Data Source
AI summary
In some aspects, a cross-species platform useful for drug discovery in neurodegenerative diseases is described.